AZ-BLUE-YONDER
29.3.2024 13:14:28 CET | Business Wire | Press release
Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately $839 million, subject to adjustments. One Network, provider of the Digital Supply Chain Network™, is known for its autonomous and resilience services and is a leading global provider of intelligent control towers. Upon completion, Blue Yonder will be well positioned to serve customers’ needs across planning, execution, commerce, and networks.
“Supply chains have become more complex, and as more and more companies reduce risk by diversifying sourcing of products globally, there is an increased demand for the sharing of information and resources across the whole value chain. This, along with increased disruptions and geopolitical risks, have put the pressure on organizations to build more resilient and robust supply chains,” said Duncan Angove, CEO, Blue Yonder. “Combined with One Network’s capabilities, Blue Yonder will establish itself as a leading supply chain solutions company that can offer a unified, end-to-end supply chain ecosystem that is resilient enough to withstand today’s challenges, and synthesized with innovative, future-focused technologies.”
The combination of One Network’s Digital Supply Chain Network™ and Blue Yonder’s supply chain capabilities create an ecosystem that:
- Offers real-time, multi-enterprise optimization, orchestration, and collaboration both inside and outside an organization – across multi-tiers from customers to carriers to suppliers to the suppliers’ suppliers.
- Allows customers to move from the order planning phase to the fulfillment phase instantly, eliminating the time gap that normally occurs from entering the order to beginning the physical fulfillment. Customers can also tap into a more complete and actionable data set across the multi-enterprise ecosystem by setting up alerts, benefiting from automation, and leveraging generative artificial intelligence (AI).
- Provides real-time visibility across the supply chain, allowing customers to take immediate action via upstream and downstream collaboration.
- Unifies disparate data silos, enabling a holistic, executive-level view into the entire supply chain – resulting in the ability to automatically optimize and execute through prescriptive real-time decision-making technology.
In addition, carriers and suppliers will be able to leverage a range of services designed specifically for their needs, including: advanced shipment scheduling management, telematics tracking and predictive insights, real-time visibility to on-time delivery trends (by site, lane, carrier, distribution center), and the ability to manage by exception.
“Supply chains continue to be fragmented and overwhelmed with disruptions. What’s needed is a unified platform that enables multi-tier orchestration, planning, and collaboration that accelerates processes with autonomous and semi-autonomous decision-making and execution across trading partners. This is the next step to creating a resilient and collaborative supply chain,” said Greg Brady, chairman and founder, One Network. “Blue Yonder offers the most complete portfolio in the industry, spanning from planning to execution. Coupled with our network and multi-enterprise, multi-tier platform, we’re poised to form a backbone of this new supply chain of the future.”
By tapping into One Network’s revolutionary platform and multi-party network, leveraged by over 150,000 trading partners, Blue Yonder’s customers will benefit from an ecosystem that:
- Accelerates end-to-end decision-making, with increased visibility into materials, resources, loads, routes, and capacity.
- Offers real-time insights and predictions, enabling the ability to take action across the supply chain ecosystem, leading to fewer disruptions and a more resilient supply chain.
- Shares data seamlessly across the entire multi-tier supply chain, including suppliers and carriers, allowing for streamlined insights into potential disruptions and the ability to mitigate risk.
- Improves supplier and carrier collaboration processes – from order creation through scheduling and fulfillment – from days to minutes, removing inaccuracies, reducing time, and decreasing cost.
- Enables the journey to autonomous supply chain management through Smart Prescriptions™, adaptive flows, and interactive visualizations, powered by proprietary AI technology.
The closing of the transaction is subject to the satisfaction of customary conditions precedent in transactions of this type, including necessary regulatory approvals, and is expected to occur in Q2 or Q3 2024. This deal is indicative of Blue Yonder's momentum in the supply chain management space, and when completed, will mark approximately $1 billion in M&A investments covering three acquisitions since Q4 2023. This announcement comes on the heels of Blue Yonder’s acquisition of flexis, offering factory planning, sequencing, and slotting capabilities, and Doddle, offering returns management and reverse logistics solutions.
About One Network Enterprises
One Network Enterprises (ONE) is a leading global provider of intelligent control towers and the Digital Supply Chain Network™. Its solutions give supply chain managers and executives end-to-end visibility and control with one data model and one truth, from raw material to last-mile delivery. Powered by NEO, One Network’s machine learning and intelligent agent technology, it enables seamless planning and execution, across inbound supply, outbound order fulfillment, and logistics, matching demand with available supply in real-time. Lead your industry by providing the highest service levels and product quality at the lowest possible cost. Visit: www.onenetwork.com
About Blue Yonder
Blue Yonder is a world leader in digital supply chain transformation. Global retailers, manufacturers, and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery, and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder – Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328293246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
